tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Troppmann C et al. Perioperative immunosuppression as a critical determinant of early outcome after discordant xenoislet transplantation: a comparative study. 1996 Transplant. Proc. pmid:8623487
McKenna BA et al. Tacrolimus (FK 506): a whole blood assay as measured on the Abbott IMx analyzer. 1996 Transplant. Proc. pmid:8623491
Stratta RJ et al. FK 506 induction and rescue therapy in pancreas transplant recipients. 1996 Transplant. Proc. pmid:8623492
Birk PE et al. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. 1996 Transplant. Proc. pmid:8623493
Alloway RR et al. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. 1996 Transplant. Proc. pmid:8623494
Woodle ES et al. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. 1996 Transplant. Proc. pmid:8623495
Appignani BA et al. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. 1996 AJR Am J Roentgenol pmid:8623651
Asfar S et al. Small bowel transplantation. A life-saving option for selected patients with intestinal failure. 1996 Dig. Dis. Sci. pmid:8625758
Fehr T et al. Antascomicins A, B, C, D and E. Novel FKBP12 binding compounds from a Micromonospora strain. 1996 J. Antibiot. pmid:8626235
Zhang BW et al. T cell responses in calcineurin A alpha-deficient mice. 1996 J. Exp. Med. pmid:8627154
Dragovich PS et al. Structure-based design of novel, urea-containing FKBP12 inhibitors. 1996 J. Med. Chem. pmid:8627611
Eberhard OK et al. How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. 1996 Transplantation pmid:8629294
Millis JM et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. 1996 Transplantation pmid:8629298
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. 1996 Arch Dermatol pmid:8629845
DiGiuseppe JA et al. Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. 1996 Arch. Pathol. Lab. Med. pmid:8629906
Bierer BE Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. 1995 Proc. Assoc. Am. Physicians pmid:8630742
Schuetz EG et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. 1996 Mol. Pharmacol. pmid:8632764
Sun S et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. 1996 Transplantation pmid:8633368
Kashu Y et al. The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. 1996 Transplantation pmid:8633382
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388
Ohtomo Y et al. C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y. 1996 Diabetologia pmid:8635672
Kinoshita I et al. Myoblast transplantation in monkeys: control of immune response by FK506. 1996 J. Neuropathol. Exp. Neurol. pmid:8642394
Singh N et al. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. 1996 Surgery pmid:8644012
Morozumi K et al. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. 1996 Transplant. Proc. pmid:8644331
Colombani PM et al. Liver transplantation in infants younger than 1 year of age. 1996 Ann. Surg. pmid:8645039
Muraoka K et al. Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. 1996 J. Clin. Invest. pmid:8647935
Pockley AG et al. Effect of cyclosporin A, FK506 and rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells. 1995 Biochem. Soc. Trans. pmid:8654800
Hisatomi A et al. Effect of Prograf (FK506) on spermatogenesis in rats. 1996 Toxicology pmid:8658548
Harihara Y et al. Effects of interferon alpha/beta on cardiac allografts. 1996 Transplant. Proc. pmid:8658645
Shinozuka N et al. Correlation between simplified immunocompetence assay and clinical graft states in kidney or liver transplant recipients. 1996 Transplant. Proc. pmid:8658649
Nishimura Y et al. Whole organ vascularized thymus allografting effectively modulates cardiac rejection. 1996 Transplant. Proc. pmid:8658660
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Watanabe K et al. Immunosuppressive effect of bactobolamine in rat liver allotransplantation. 1996 Transplant. Proc. pmid:8658697
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
Yagura K et al. Pharmacokinetic characteristics of two types of liposomal FK 506. 1996 Transplant. Proc. pmid:8658708
Ogawa N et al. Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation. 1996 Transplant. Proc. pmid:8658710
Yoshida Y et al. Effect of lipoprostaglandin E1 in concordant xenografts. 1996 Transplant. Proc. pmid:8658716
Kawauchi M et al. Which are the target vessels of xeno- and allo-lung rejection?--a primate single lung transplantation study. 1996 Transplant. Proc. pmid:8658719
Sakimoto H et al. Administration of tacrolimus (FK506) in hamster-to-rat pancreas xenotransplantation. 1996 Transplant. Proc. pmid:8658727
Takeda M et al. Pretreatment with splenectomy and FK506 in xeno-lung transplantation. 1996 Transplant. Proc. pmid:8658728
Zou XM et al. Immunosuppressive effect of FK506 on orthotopic liver and small bowel xenotransplantation (xenoOLTx and SBTx). 1996 Transplant. Proc. pmid:8658729
Kokado Y et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. 1996 Transplant. Proc. pmid:8658802
Park KM et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. 1996 Transplant. Proc. pmid:8658863
Kakefuda T et al. Detection of nitrosylhemoglobin in liver allograft in rats by using near-infrared spectroscopy. 1996 Transplant. Proc. pmid:8658885
Kawabe A et al. Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. 1996 Transplant. Proc. pmid:8658893
Hayakawa K et al. Maintenance of unresponsiveness by short-term pulse therapy with FK 506 in rat transplantation. 1996 Transplant. Proc. pmid:8658904
Ishikawa M et al. Acetaminophen absorption test as a useful indicator of small intestinal rejection in rats. 1996 Transplant. Proc. pmid:8658911
Kawano K et al. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. 1996 Transplant. Proc. pmid:8658938
Kanzler S et al. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A. 1996 Z Gastroenterol pmid:8659188
Schaefer A et al. Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells. The role of calcineurin. 1996 J. Biol. Chem. pmid:8662717
Owens-Grillo JK et al. A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains. 1996 J. Biol. Chem. pmid:8662874
Kralli A and Yamamoto KR An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. 1996 J. Biol. Chem. pmid:8663352
Tokunaga Y and Alak AM FK506 (tacrolimus) and its immunoreactive metabolites in whole blood of liver transplant patients and subjects with mild hepatic dysfunction. 1996 Pharm. Res. pmid:8668663
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Kay JE Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. 1996 Biochem. J. pmid:8670043
Schmaldienst S and Horl WH Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. 1996 Nephrol. Dial. Transplant. pmid:8672015
Hall MN The TOR signalling pathway and growth control in yeast. 1996 Biochem. Soc. Trans. pmid:8674674
Mattila PS The actions of cyclosporin A and FK506 on T-lymphocyte activation. 1996 Biochem. Soc. Trans. pmid:8674715
Adams DH and Liu Q FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients. 1996 Hepatology pmid:8675167
Halloran PF Molecular mechanisms of new immunosuppressants. 1996 Clin Transplant pmid:8680047
Pullicino P et al. Posterior leucoencephalopathy syndrome. 1996 Lancet pmid:8684128
Pirenne J et al. Combined transplantation of small and large bowel. FK506 versus cyclosporine A in a porcine model. 1996 Transplantation pmid:8685944
Tsugita M et al. Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. 1996 Transplantation pmid:8685952
Huntress JD and Papadakos PJ The role of calcium-channel antagonists in solid organ transplantation. 1996 New Horiz pmid:8689268
Lampen A et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. 1995 Drug Metab. Dispos. pmid:8689938
Luan S et al. Molecular characterization of a FKBP-type immunophilin from higher plants. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8692927
Bashuda H et al. Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. 1996 Transplantation pmid:8693525
Fung JJ et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. 1996 J. Am. Coll. Surg. pmid:8696542
Shaw LM et al. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. 1996 Clin. Chem. pmid:8697605
Bousvaros A et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). 1996 Gastroenterology pmid:8698205
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Hemenway CS and Heitman J Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 1996 J. Biol. Chem. pmid:8702500
Tyedmers J et al. Efficient folding of firefly luciferase after transport into mammalian microsomes in the absence of luminal chaperones and folding catalysts. 1996 J. Biol. Chem. pmid:8702642
Raufman JP et al. Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach. Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion. 1996 J. Biol. Chem. pmid:8702699
Timerman AP et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. 1996 J. Biol. Chem. pmid:8702774
Shih M and Malbon CC Protein kinase C deficiency blocks recovery from agonist-induced desensitization. 1996 J. Biol. Chem. pmid:8702931
Okadome T et al. Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. 1996 J. Biol. Chem. pmid:8702959
Rahfeld JU et al. Isolation and amino acid sequence of a new 22-kDa FKBP-like peptidyl-prolyl cis/trans-isomerase of Escherichia coli. Similarity to Mip-like proteins of pathogenic bacteria. 1996 J. Biol. Chem. pmid:8703024
Hartley AD et al. cAMP inhibits bud growth in a yeast strain compromised for Ca2+ influx into the Golgi. 1996 Mol. Gen. Genet. pmid:8709962
Tokime T et al. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. 1996 Neurosci. Lett. pmid:8710192
Christophers E Psoriasis: mechanisms and entry points for possible therapeutic interventions. 1996 Australas. J. Dermatol. pmid:8713012
Frezza EE et al. Small bowel transplantation: current progress and clinical application. 1996 Mar-Apr Hepatogastroenterology pmid:8714229
Shultz SL and Meriney DK Cyclosporine and tacrolimus: a comparison of immunosuppressants used for liver transplantation. 1996 Jul-Aug Dimens Crit Care Nurs pmid:8717641
Alak AM and Lizak P Stability of FK506 in blood samples. 1996 Ther Drug Monit pmid:8721287
Yu C et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. 1996 Bone Marrow Transplant. pmid:8722370
Fealy MJ and Press BH Pinpointing the moment of allograft rejection. 1996 J Hand Surg Am pmid:8724501
Hashino S et al. Antitumor effect in cyclosporine A- or FK506-treated mice after syngeneic bone marrow transplantation. 1996 Leuk. Lymphoma pmid:8726416
Soubrane O and Houssin D [Liver transplantation. Current aspects]. 1996 Presse Med pmid:8728904
Lampen A et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. 1996 Br. J. Pharmacol. pmid:8732283
Saada V et al. Comparative evaluation of in vitro and in vivo immunosuppressive potential of cyclosporin G with cyclosporin A and FK-506. 1996 Int. J. Immunopharmacol. pmid:8732436
Asante-Korang A et al. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. 1996 J. Heart Lung Transplant. pmid:8732602
Herzog D et al. Combined bowel-liver transplantation in an infant with microvillous inclusion disease. 1996 J. Pediatr. Gastroenterol. Nutr. pmid:8732907
Okada K et al. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. 1996 Ophthalmologica pmid:8738464
Wagner K et al. Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. 1996 Clin. Nephrol. pmid:8738666
Hohage H et al. Influence of cyclosporine A and FK506 on 24 h blood pressure monitoring in kidney transplant recipients. 1996 Clin. Nephrol. pmid:8738668
Herget S et al. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. 1996 Clin. Nephrol. pmid:8738671